Genmab is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.

Third Quarter 2014 Financial Results

Genmab will report its Third Quarter 2014 financial results after market close on November 5. An investor conference call to discuss the results will be held at 6PM CET/12PM EST on November 5. To join the call by phone, dial one of the following numbers and ask for the Genmab conference call:  +45 3272 8018 in Denmark, +44 1452 555 131 in the UK or +1 866 682 8490 in the US. Click here to listen to the webcast.

Envisioning the Future of Cancer Treatment: A Video with CEO Jan van de Winkel

Genmab's CEO shares his perspective on how the company's work to develop innovative antibody therapeutics could change the lives of cancer patients in the future.  Click here to watch the video.

Genmab Opens Doors to Innovation

Genmab is inviting researchers in academia and industry to experience the full power of the DuoBody® platform for bispecific antibody research and drug development. Explore the possibilities via our recently published Perspective in the journal mAbs and the renewed Open Innovation section on

Latest news


  • At the heart of Genmab is a deep desire to improve the quality of life for cancer patients.
  • Click here to watch our video about our fight against cancer.


Stock Price as of 10/31/2014 12:00 AM (CET)

  • Share Price DKK 258.90
  • Change (in DKK) 4.90
  • Volume 327542

Stock Information